Ultragenyx Pharmaceutical (RARE) Free Cash Flow Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.41% |
| Dec 31, 2025 | -3.40% |
| Sep 30, 2025 | -7.11% |
| Jun 30, 2025 | -27.27% |
| Mar 31, 2025 | -8.86% |
| Dec 31, 2024 | 0.99% |
| Sep 30, 2024 | 4.85% |
| Jun 30, 2024 | 4.08% |
| Mar 31, 2024 | -14.20% |
| Dec 31, 2023 | 2.05% |
| Sep 30, 2023 | -17.09% |
| Jun 30, 2023 | -7.86% |
| Mar 31, 2023 | -13.04% |
| Dec 31, 2022 | -1.81% |
| Sep 30, 2022 | -8.04% |
| Jun 30, 2022 | -8.94% |
| Mar 31, 2022 | -18.20% |
| Dec 31, 2021 | -12.94% |
| Sep 30, 2021 | -20.37% |
| Jun 30, 2021 | -13.83% |
| Mar 31, 2021 | -30.54% |
| Dec 31, 2020 | -14.78% |
| Sep 30, 2020 | -15.08% |
| Jun 30, 2020 | 46.12% |
| Mar 31, 2020 | -43.24% |
| Dec 31, 2019 | -50.00% |
| Sep 30, 2019 | -49.48% |
| Jun 30, 2019 | -56.17% |
| Mar 31, 2019 | -54.60% |
| Dec 31, 2018 | -41.94% |
| Sep 30, 2018 | -58.80% |
| Jun 30, 2018 | -56.37% |
| Mar 31, 2018 | -69.29% |